Depomed, Inc. Completes Enrollment of Breeze 3 Phase 3 Clinical Trial for Non-Hormonal Treatment in Menopausal Hot Flashes

MENLO PARK, Calif., March 3, 2011 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) announced today that it has completed enrollment of Breeze 3, the company’s pivotal Phase 3 clinical trial evaluating Serada® (extended release gabapentin tablets) for the non-hormonal treatment of menopausal hot flashes.